"We welcome the Medicare GLP-1 Bridge as an important step in getting Wegovy to more patients and will continue to work with CMS, healthcare professionals, pharmacists, and patient advocates to support implementation and help eligible seniors access the care they need and deserve." The Medicare GLP-1 Bridge provides eligible patients access to Wegovy for weight management
Lillys vanguard offering on the platform is Zepbound, a new GLP-1 drug designed for weight loss that uses the same active ingredient (tirzepatide) found in its diabetes treatment, Mounjaro
For a more holistic, gradual fat loss approach, CJC-1295 may be preferable due to its sustained effects
Maria Daniela Hurtado Andrade, endocrinologist at Mayo Clinic and senior author of the study, said: In this observational study, women who used menopausal hormone therapy lost about 35 per cent more weight than women taking tirzepatide alone